Literature DB >> 1907278

Catalytic triad residue mutation (Asp156----Gly) causing familial lipoprotein lipase deficiency. Co-inheritance with a nonsense mutation (Ser447----Ter) in a Turkish family.

F Faustinella1, A Chang, J P Van Biervliet, M Rosseneu, N Vinaimont, L C Smith, S H Chen, L Chan.   

Abstract

We studied the molecular basis of familial Type I hyperlipoproteinemia in two brothers of Turkish descent who had normal plasma apolipoprotein C-II levels and undetectable plasma post-heparin lipoprotein lipase (LPL) activity. We cloned the cDNAs of LPL mRNA from adipose tissue biopsies obtained from these individuals by the polymerase chain reaction and directional cloning into M13 vectors. Direct sequencing of pools of greater than 2000 cDNA clones indicates that their LPL mRNA contains two mutations: a missense mutation changing codon 156 from GAU to GGU predicting an Asp156----Gly substitution and a nonsense mutation changing the codon for Ser447 from UCA to UGA, a stop codon, predicting a truncated LPL protein that contains 446 instead of 448 amino acid residues. Both patients were homozygous for both mutations. Analysis of genomic DNAs of the patients and their family members by the polymerase chain reaction, restriction enzyme digestion (the GAT----GGT mutation abolishes a TaqI restriction site), and allele-specific oligonucleotide hybridization confirms that the patients were homozygous for these mutations at the chromosomal level, and the clinically unaffected parents and sibling were true obligate heterozygotes for both mutations. In order to examine the functional significance of the mutations in this family, we expressed wild type and mutant LPLs in vitro using a eukaryotic expression vector. Five types of LPL proteins were produced in COS cells by transient transfection: (i) wild type LPL, (ii) Asp156----Gly mutant, (iii) Ser447----Ter mutant, (iv) Gly448----Ter mutant, and (v) Asp156----Gly/Ser447----Ter double mutant. Both LPL immunoreactive mass and enzyme activity were determined in the culture media and intracellularly. Immunoreactive LPLs were produced in all cases. The mutant LPLs, Asp156----Gly and Asp156----Gly/Ser447----Ter, were devoid of enzyme activity, indicating that the Asp156----Gly mutation is the underlying defect for the LPL deficiency in the two patients. The two mutant LPLs missing a single residue (Gly448) or a dipeptide (Ser447-Gly448) from its carboxyl terminus had normal enzyme activity. Thus, despite its conservation among all mammalian LPLs examined to date, the carboxyl terminus of LPL is not essential for enzyme activity. We further screened 224 unrelated normal Caucasians for the Ser447----Ter mutation and found 36 individuals who were heterozygous and one individual who was homozygous for this mutation, indicating that it is a sequence polymorphism of no functional significance. Human LPL shows high homology to hepatic triglyceride lipase and pancreatic lipase.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907278

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  A missense mutation (Trp86----Arg) in exon 3 of the lipoprotein lipase gene: a cause of familial chylomicronemia.

Authors:  K Ishimura-Oka; F Faustinella; S Kihara; L C Smith; K Oka; L Chan
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

Review 2.  Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Authors:  Werner J Geldenhuys; Li Lin; Altaf S Darvesh; Prabodh Sadana
Journal:  Drug Discov Today       Date:  2016-10-19       Impact factor: 7.851

3.  The -93T/G LPL Promoter Polymorphism Is Associated With Lower Third-Trimester Triglycerides in Pregnant African American Women.

Authors:  Mandy J Schmella; Robert E Ferrell; Marcia J Gallaher; David L Lykins; Andrew D Althouse; James M Roberts; Carl A Hubel
Journal:  Biol Res Nurs       Date:  2015-01-07       Impact factor: 2.522

4.  Comparative studies of vertebrate lipoprotein lipase: a key enzyme of very low density lipoprotein metabolism.

Authors:  Roger S Holmes; John L Vandeberg; Laura A Cox
Journal:  Comp Biochem Physiol Part D Genomics Proteomics       Date:  2011-04-22       Impact factor: 2.674

5.  Biochemical Analysis of the Lipoprotein Lipase Truncation Variant, LPLS447X, Reveals Increased Lipoprotein Uptake.

Authors:  Cassandra K Hayne; Michael J Lafferty; Brian J Eglinger; John P Kane; Saskia B Neher
Journal:  Biochemistry       Date:  2017-01-09       Impact factor: 3.162

6.  The lipoprotein lipase (LPL) S447X gain of function variant involves increased mRNA translation.

Authors:  Gouri Ranganathan; Resat Unal; Irina D Pokrovskaya; Preeti Tripathi; Jerome I Rotter; Mark O Goodarzi; Philip A Kern
Journal:  Atherosclerosis       Date:  2011-12-27       Impact factor: 5.162

7.  Prevention of hyperlipidemic acute pancreatitis during pregnancy with medium-chain triglyceride nutritional support.

Authors:  T Mizushima; K Ochi; N Matsumura; M Ichimura; T Ishibashi; K Tsuboi; H Harada
Journal:  Int J Pancreatol       Date:  1998-06

8.  Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes.

Authors:  D E Wilson; A Hata; L K Kwong; A Lingam; J Shuhua; D N Ridinger; C Yeager; K C Kaltenborn; P H Iverius; J M Lalouel
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

9.  Dyslipidaemia in a boy with recurrent abdominal pain, hypersalivation and decreased lipoprotein lipase activity.

Authors:  D Matern; H Seydewitz; H Niederhoff; H Wiebusch; M Brandis
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

Review 10.  Molecular genetics of human lipoprotein lipase deficiency.

Authors:  M R Hayden; Y Ma
Journal:  Mol Cell Biochem       Date:  1992-08-18       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.